Full TitleA Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy using 131I-omburtomab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases.
The purpose of this study is to assess the safety and effectiveness of 131I-omburtamab radioimmunotherapy in children and teens with neuroblastoma that has spread to the brain or spinal cord or the lining around the brain. Omburtamab is an antibody that attaches to neuroblastoma cells. It carries radioactive iodine (131I) directly to the cancer cells, killing them. The treatment is given by several injections into a tube that feeds into the spinal fluid surrounding the brain.
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have neuroblastoma that has spread to the brain or spinal cord or the lining around the brain.
- This study is for patients under age 18
For more information about this study and to inquire about eligibility, please contact Dr. Kim Kramer at 212-639-3751.